Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

A major boardroom shake-up at Novo Nordisk has given the Novo Nordisk Foundation an unprecedented level of control, raising ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.

Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying ...

Prescription-drug costs were the top-cited factor for rising premiums, according to large businesses surveyed by the think tank. Two-thirds of large businesses said GLP-1s for weight loss had a ...

Trisha Durant has joined Alvotech as SVP of global business development and commercial operation, ex-North America. Harshika ...

This episode of Pharma Pulse covers MJH Life Sciences’ acquisition of BPD Healthcare to deepen its reach into hospitals and ...

Novo Nordisk A/S (NYSE: NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard ...